Neoplasms
16 competing products in clinical development for Neoplasms.
Pipeline by Phase
Phase 112
Phase 1/22
Phase 21
Phase 31
All Products (16)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Encorafenib + Cetuximab + Oxaliplatin + Irinotecan + Leucovorin + 5-FU + Capecitabine + Bevacizumab | Ono Pharmaceutical | Phase 3 | Active | 44 |
| enzastaurin | Eli Lilly | Phase 2 | Completed | 35 |
| LY3295668 | Eli Lilly | Phase 1/2 | Completed | 32 |
| Galunisertib + Gemcitabine + Placebo | Eli Lilly | Phase 1/2 | Completed | 32 |
| AB0024 | Gilead Sciences | Phase 1 | Completed | 29 |
| 852A | Pfizer | Phase 1 | Completed | 29 |
| IMC-3C5 | Eli Lilly | Phase 1 | Completed | 29 |
| RO5212054 | Roche | Phase 1 | Completed | 29 |
| RO6895882 | Roche | Phase 1 | Completed | 29 |
| MORAb-003 | Eisai | Phase 1 | Completed | 29 |
| E7820 | Eisai | Phase 1 | Completed | 29 |
| TTI-237 | Pfizer | Phase 1 | Terminated | 21 |
| KHK2866 + Gemcitabine and Carboplatin + paclitaxel + pegylated liposomal doxorubicin | Kyowa Kirin | Phase 1 | Terminated | 21 |
| ADC-1013 | Alligator Bioscience AB | Phase 1 | Completed | 19 |
| VIP152 (BAY 1251152) + VIP152 (BAY 1251152) 30 mg + Keytruda + VIP152 (BAY 1251152) 15 mg | Vincerx Pharma | Phase 1 | Completed | 19 |
| VIP236 (Q3W) + VIP236 (Q2W) | Vincerx Pharma | Phase 1 | Completed | 19 |